Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database

Kaczmarek, Emilie; Saint-Martin, C.; Pierga, J-Y; Brain, Étienne; Rouzier, Roman; Savignoni, Alexia; Mouret-Fourme, E.; Dièras, Véronique; Piot, Irwin; Dubot, Coraline; Carton, Matthieu; Lerebours, Florence

doi:10.1007/s10549-019-05423-5

Cited by 7 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En Colombia se reportaba la misma tendencia, independientemente si la evaluación molecular se realizaba por inmunohistoquímica o FISH (20). Lo mismo ocurre en Francia, donde canónicamente ya es considerado un factor de mal pronóstico, pero la importancia actual de identificar poblaciones específicas se da porque predice la respuesta al tratamiento con anticuerpos monoclonales (21). En México, los pacientes Her2/neu positivos (25,6% de 125 casos) representaron el grupo con mayor porcentaje de metástasis durante el seguimiento (22).…”

Section: Discussionunclassified

Inmunohistoquímica con anticuerpos monoclonales en mujeres indígenas peruanas con cáncer de mama, para pronosticar sobrevida global

Manrique

Mamani²,

Díaz³

2021

Rev. colomb. cancerol.

View full text Add to dashboard Cite

Objetivo: Aplicar la técnica de anticuerpos monoclonales para HER2/neu (human epidermal growth 2/neuro glioblastoma), en indígenas nativos de Perú con diagnòstico de cáncer de mama, así como correlacionar la sobreexpresión molecular con la sobrevida global. Pacientes y Métodos: Estudio experimental, prospectivo y analítico. Se evaluaron 23 muestras biològicas de pacientes indìgenas andinos de Arequipa, con diagnòstico definitivo de adenocarcinoma de mama. La expresión del receptor HER2/neu se determinó mediante inmunohistoquímica con anticuerpos monoclonales. Resultados: El 43,4% (10 casos) fueron positivos para sobreexpresión del receptor. Los casos negativos fueron 56,6%. La supervivencia global a los 3 años fue del 69,9% para los HER2/neu sobreexpresados y 84,6% para los negativos, mostrando diferencia estadísticamente significativa (p=0,017). Conclusiones: Es factible aplicar la técnica de inmunohistoquìmica en indìgenas andinos con càncer de mama. Asìmismo hubo correlaciòn entre la sobreexpresión del receptor HER2/neu con menor sobrevida global. El principal beneficio de esta tècnica es justificar el uso de terapia biológica con anticuerpos monoclonales, segùn el perfil molecular, en poblaciòn nativa de Arequipa.

show abstract

Section: Discussionunclassified

Inmunohistoquímica con anticuerpos monoclonales en mujeres indígenas peruanas con cáncer de mama, para pronosticar sobrevida global

Manrique

Mamani²,

Díaz³

2021

Rev. colomb. cancerol.

View full text Add to dashboard Cite

show abstract

“…Approximately half of a million women die of breast cancer each year, and its incidence is increasing 2 . Surgery, radiation therapy, and chemotherapy are the main breast cancer treatments 3 . Currently, the development of accurate diagnostic methods and the prediction of treatment outcomes have become hot topics in breast cancer research 4 …”

Section: Introductionmentioning

confidence: 99%

“…2 Surgery, radiation therapy, and chemotherapy are the main breast cancer treatments. 3 Currently, the development of accurate diagnostic methods and the prediction of treatment outcomes have become hot topics in breast cancer research. 4 Currently, neoadjuvant chemotherapy (NAC) has been widely used as an important component of systemic treatment before surgery or radiotherapy for locally advanced breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast‐enhanced ultrasound and dynamic contrast‐enhanced magnetic resonance imaging

et al. 2022

View full text Add to dashboard Cite

This study aimed to evaluate the value of dynamic contrast‐enhanced ultrasound (CEUS) combined with dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) in predicting pathological complete response (pCR) in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). Fifty‐seven female patients with breast cancer (mean age, 50.46 years; range, 32–66 years) scheduled for NAC were recruited. CEUS and DCE‐MRI were performed before and after NAC. Imaging features and their changes were compared with postoperative pathological results. After the clinical differences were balanced using propensity score matching, univariate and multiple logistic regression analyses were used to derive the characteristics independently associated with pCR. Receiver operating characteristic curve analysis was performed to assess diagnostic performance. After six to eight cycles of NAC, 24 (42.1%) patients achieved pCR, while 33 (57.9%) did not. Multivariate analysis showed that enhancement order on CEUS and DCE‐MRI before NAC, reduction in diameter and enhancement shape on CEUS, maximum diameter on DCE‐MRI, and the type of progressive dynamic contrast enhancement after NAC were independently associated with pCR after NAC. The area under the receiver operating characteristic curve for CEUS+DCE‐MRI was 0.911 (95% confidence interval, 0.826–0.997), and the specificity and positive predictive values were 87.0% and 87.5%. CEUS and DCE‐MRI have the potential for assessing the pathological response to NAC in patients with breast cancer; their combination showed the best diagnostic performance. CEUS+DCE‐MRI has proved beneficial for comprehensive assessment and personalizing treatment strategies for patients with breast cancer.

show abstract

“…1 With the development of early diagnostic techniques and the emergence of more effective molecular targeted therapeutic drugs, such as tamoxifen 2 and trastuzumab, 3 the efficiency of breast cancer treatment has improved and the survival rate for breast cancer patients has increased markedly during the past decades. 4,5 However, to further improve the efficiency of breast cancer treatment is a new challenge due to the development of treatment resistance and side effects. [6][7][8] Currently, immunotherapy is considered as a promising treatment option for cancer, 9 and adoptive cytokine-induced killer (CIK) cell transfer is commonly used in a variety of tumor immunotherapeutic strategies due to its advantage.…”

Section: Introductionmentioning

confidence: 99%

<p><sup>18</sup>F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model</p>

Yin

et al. 2020

OTT

View full text Add to dashboard Cite

Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database

Cited by 7 publications

References 26 publications

Inmunohistoquímica con anticuerpos monoclonales en mujeres indígenas peruanas con cáncer de mama, para pronosticar sobrevida global

Inmunohistoquímica con anticuerpos monoclonales en mujeres indígenas peruanas con cáncer de mama, para pronosticar sobrevida global

Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast‐enhanced ultrasound and dynamic contrast‐enhanced magnetic resonance imaging

<p><sup>18</sup>F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model</p>

Contact Info

Product

Resources

About